Surrozen to Present at Canaccord Genuity’s 41st Annual Growth Conference
Surrozen Inc. (Nasdaq: SRZN) has announced that CEO Craig Parker will present a company overview and business update at Canaccord Genuity’s 41st Annual Growth Conference on August 12, 2021, at 9:30 a.m. ET. Interested parties can access the live webcast on Surrozen's website, with a replay available afterward.
Surrozen focuses on developing drug candidates that selectively modulate the Wnt pathway, with applications in inflammatory bowel disease, hepatitis, eye diseases, and more. For further details, visit surrozen.com.
- None.
- None.
Insights
Analyzing...
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc. (Nasdaq: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced that Craig Parker, chief executive officer, will provide a company overview and a business update at Canaccord Genuity’s 41st Annual Growth Conference at 9:30 a.m. ET on Thursday, August 12. Interested parties may access the live webcast via the Investors section of the Surrozen website at www.surrozen.com. A replay of the webcast will be archived on the website.
About Surrozen
Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential application across multiple disease areas, including inflammatory bowel disease, hepatitis, eye diseases, hearing loss, lung and airway diseases, and certain neurological disorders. For more information, please visit surrozen.com.
Media Contact:
Ian Stone, Managing Director
CanaleComm
Tel.: (619) 518-3518
Email: ian.stone@canalecomm.com
FAQ
What is the date and time of Surrozen’s presentation at the Canaccord Genuity Growth Conference?
How can I access the live webcast of Surrozen's conference presentation?
What is the focus of Surrozen Inc. and its drug candidates?
What diseases is Surrozen targeting with its therapies?
